Comparative pharmacokinetics of ceftazidime and moxalactam.
The pharmacokinetics of ceftazidime and moxalactam were compared after intravenous and intramuscular administration of single 1-g doses to eight healthy volunteers in a crossover study. The bioavailability of the antibiotics after administration by either route was almost complete. Both drugs had similar areas under the serum curves. Significant differences between ceftazidime and moxalactam were observed with respect to the apparent volume of distribution (18.4 and 24.1 liters, respectively), to the terminal half-life (1.6 versus 2.0 h), and to urinary recovery of the active compound (96 versus 79%). Ceftazidime was almost completely eliminated by renal excretion (greater than 96%), whereas about 20% of the moxalactam was eliminated by nonrenal mechanisms. The concentrations of ceftazidime and moxalactam in serum after a 1-g dose exceeded the concentrations required to inhibit 90% of the Enterobacteriaceae for about 8 and 10 h, respectively. The levels of ceftazidime and moxalactam in serum exceeded the 90% minimal inhibitory concentration of Pseudomonas aeruginosa for about 6 and 1 h, respectively.
D000328:Adult; D001682:Biological Availability; D002442:Ceftazidime / Q000008:administration & dosage / Q000378:metabolism*; D004361:Drug Tolerance; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D006207:Half-Life; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007668:Kidney / Q000378:metabolism; D007700:Kinetics; D008297:Male; D009070:Moxalactam / Q000008:administration & dosage / Q000378:metabolism*; D011552:Pseudomonas Infections / Q000188:drug therapy
D002442:Ceftazidime; D009070:Moxalactam